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OBJECTIVE — Insulin has opposing inﬂuences on blood pressure by simultaneously in-
creasing adrenergic activity and vasodilatating peripheral blood vessels. In this study, we sought
to determine whether hyperinsulinemia affects tilt table responses in older adults with type 2
diabetes not complicated by orthostatic hypotension.
RESEARCH DESIGN AND METHODS — Twenty-two older adults (mean age 71.7 
1.1) with diet-controlled or oral hypoglycemic drug–controlled type 2 diabetes were recruited.
All subjects with orthostatic hypotension, diabetic nephropathy, and sensory neuropathy were
excluded. Subjects underwent euglycemic-hyperinsulinemic clamp and placebo “sham clamp”
sessions. Sequential euglycemic-hyperinsulinemic clamps were performed for 2 h at 40 mU  
m
2   min
1 (low dose) and 2 h at 80 mU   m
2   min
1 (high dose), and each was followed by
a head-up tilt table test at 70°C for 10 min.
RESULTS — There were no incidents of presyncope during the sham clamp, whereas there
were four presyncopal events during both the low-dose and high-dose tilts. Although the low-
dose clamp showed no difference in the response between sessions (two-way ANOVA), subjects
demonstrated a signiﬁcantly larger decrease in mean arterial pressure (P  0.005) and diastolic
blood pressure (P  0.08) during the high-dose tilt. Doppler measures of middle cerebral artery
velocity were no different between the two sessions at either dose.
CONCLUSIONS — Thevasodilatoryresponsetoinsulincanunmaskorthostaticintolerance
in older adults with type 2 diabetes, resulting in presyncopal symptoms. This could contribute
to orthostatic hypotension in combination with other factors such as hyperthermia, hypovole-
mia, and adverse effects from medications.
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O
rthostatic hypotension is common
inolderadultswith(1)andwithout
diabetes (2) and is usually attrib-
uted to autonomic neuropathy or age-
related comorbidities (3). Insulin has
profound cardiovascular properties, re-
sulting in simultaneous adrenergic (4)
and vasodilatory (5,6) responses that
have opposing inﬂuences on blood pres-
sure. Depending on the relative magni-
tude of sympathetic activation and
vasodilation in older adults, insulin ad-
ministration might be a contributing fac-
tor in orthostatic intolerance and
syncope.
Epidemiologicalstudieshavedemon-
strated that the use of insulin is a risk fac-
torforsyncopeinolderadults(7)andthat
insulin hypersensitivity is a predisposing
factor for vasovagal syncope in young
women (8). Previous work in young
adultswithtype1diabeteshasshownthat
insulin has no impact on standing blood
pressure unless their diabetes is already
complicated by autonomic neuropathy
(9). However, the aging process itself is
associated with a reduction in adrenergic
sensitivity (10). Insensitivity to an insu-
lin-mediated increase in adrenergic activ-
ity could allow the vasodilatory response
to predominate and potentially uncover
“latent” orthostatic hypotension in older
adults with uncomplicated diabetes, sim-
ilar to that demonstrated previously in
young hyperthermic adults with diabetes
(11).
In the current study, we examined in
olderadultswithtype2diabetes(without
baseline orthostatic hypotension) the im-
pact of hyperinsulinemia (12) on arterial
blood pressure and Doppler measures of
cerebral blood ﬂow during upright tilt.
Wehypothesizedthatinolderadultswith
type 2 diabetes, the cardiovascular effects
of insulin would precipitate orthostatic
intolerance not present at baseline.
RESEARCH DESIGN AND
METHODS— Twenty-ﬁve older
adults, ranging in age from 65 to 80
years (21 men and 4 women, mean age
71.7  1.1 years) were recruited (Table
1). All subjects had to be aged 65 years,
and subjects were excluded if they had
any history of syncope, presyncope, an-
gina, myocardial infarction, stroke, hy-
pertension, chronic pulmonary disease,
or smoking in the last 5 years. Hyperten-
sionwasdeﬁnedasanaveragebloodpres-
sure measurement (based on three
measurements)withasystolicbloodpres-
sure 160 mmHg or a diastolic blood
pressure 90 mmHg. Subjects were also
excludediftheytook-blockers,calcium
channel blockers, or any other agent with
the potential to inﬂuence autonomic
function. Entry requirements included
normal results for the following: blood
pressure, physical examination, resting
electrocardiogram, hematocrit, fasting
blood glucose, total cholesterol, and cre-
atinine. All subjects had to have had a
diagnosis of type 2 diabetes for at least 5
years. On this basis we excluded three
subjects (n  22).
With respect to diabetes complica-
tions, subjects were excluded if they had
evidence of sensory neuropathy on phys-
ical examination (done by physician) as
shown by the response to light touch,
pain(pinprick),andvibrationsense.Sub-
jectswithorthostatichypotensionatbase-
line were excluded during the initial
screening visit by a series of ﬁve ortho-
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neuver consisted of changing position
from lying to standing for 3 min and was
followed by a 5-min rest period. Ortho-
static hypotension was deﬁned as a drop
in systolic blood pressure 20 mmHg
during one of these maneuvers (13).
This study was approved by the Hu-
man Subjects Committee of the Univer-
sity of British Columbia. All subjects gave
written informed consent.
Each subject underwent two sessions
(insulin clamp and “sham clamp”) occur-
ring in random order on different days
(maximum time between sessions was 28
days). All study sessions were performed
with the subject supine and occurred be-
tween 7 A.M. and noon for all subjects to
avoidbiasduetocircadianrhythms.Each
subject was supine for 45 min before the
start of data collection to reach steady
state. Subjects were fasting, had refrained
from the consumption of alcohol or caf-
feine, and had not exercised for the 24 h
before each session. Both the subject and
the technician responsible for monitoring
blood pressure, heart rate, and cerebral
Doppler measures were blinded to the
sessiontype.Thestudyroomwastemper-
ature controlled (25  1°C).
Euglycemic-hyperinsulinemic clamp
During the insulin clamp session, each
subject underwent a euglycemic-
hyperinsulinemic infusion initially at 40
mU   m
2   min
1 (low dose) and then at
80mU m
2 min
1(highdose),roughly
corresponding to the peak insulin level
that occurs after subcutaneous injections
of insulin (0.1 and 0.2 unit/kg Novolin R)
(14). Each insulin infusion was adminis-
tered for 2 h and was then followed by a
10-min tilt (see below). Previous work
has demonstrated that2ho feuglycemic
hyperinsulinemia results in signiﬁcant
peripheral vasodilatation (6). In all stud-
ies, 18-gauge needles were inserted into
anantecubitalveinforinfusionofglucose
and into a contralateral hand vein for
sampling of “arterialized” venous blood.
Because there is a signiﬁcant gradient be-
tween arterial and venous glucose values,
the patient’s hand is placed in a warming
chamber, which results in sufﬁcient arte-
riovenousshuntingto“arterialize”venous
blood, avoiding arterial catheterization
(15). A primed continuous infusion of in-
sulin (low dose 40 mU   m
2   min
1 and
high dose 80 mU   m
2   min
1) was be-
gun using the euglycemic-hyperinsuline-
mic clamp technique and continued for
140 min (2 h plus 10 min for the tilt table
test). Blood glucose was maintained at
basal levels (determined at the start of the
ﬁrst session) using the euglycemic-
hyperinsulinemic clamp protocol (16).
Plasmaglucosewasmeasuredevery5min
and analyzed immediately using a YSI
glucose analyzer (YSI Life Sciences, Yel-
low Springs, OH). Plasma insulin was
measured every 15 min as described pre-
viously (17).
Tilt table protocol
Each 2-h euglycemic-hyperinsulinemic
clamp (at both low and high doses) was
followed by a 70° head-up tilt for 10 min.
During all clamps and during each up-
right tilt heart rate, blood pressure and
middle cerebral artery (MCA) velocity
were measured continuously (see below),
and an average was determined for each
minute. The tilt table test was aborted be-
fore 10 min if the subjects demonstrated
presyncopal symptoms in association
with at least a 30 mmHg drop in blood
pressure compared with baseline or de-
veloped outright syncope.
Data collection and processing
Heart rate was monitored continuously
using a three-lead electrocardiogram.
Blood pressure was monitored using a
Finometer (Finapres Medical Systems,
Amsterdam, the Netherlands). The Fin-
ometermeasuresbeat-to-beatbloodpres-
sure noninvasively using infrared
plethysmography through a ﬁnger cuff.
Use of the Finometer and infrared pleth-
ysmography for monitoring blood pres-
sure changes has been well established as
a noninvasive measure of beat-to-beat
blood pressure (18) and has been exten-
sively validated against intra-arterial
bloodpressuremonitoringinolderadults
(19).TheFinometeruseswaveformﬁlter-
ing,levelcorrection,andanadditionalre-
turn-to-ﬂow calibration to reconstruct
brachial artery pressures (20).
Transcranial Doppler measures of
MCA blood ﬂow velocity was assessed
during upright tilt following previously
published methods (21). After a temporal
ultrasonic bone window was conﬁrmed,
the right MCA was insonated using M-
mode ultrasonography with a 2-MHz
TCD probe (Spencer Technologies, Seat-
tle, WA), which was ﬁxed in place by a
ﬁxation device (Spencer Technologies).
The electrocardiogram, blood pressure,
and transcranial Doppler signal were
sampled at 1,000 Hz (AD Instruments)
and digitized for later analysis. Beat-to-
beat measures of blood pressure (Beat-
scope; Finapres Medical Systems) and
heart rate (Powerlab; AD Instruments)
werecalculatedusingcommerciallyavail-
ablesoftware.WithrespecttoMCAveloc-
ity measures, beat-to-beat measures of
systolic (SBFV), diastolic (DBVF), and
mean cerebral blood ﬂow (MBFV) veloc-
ities were calculated as described previ-
ously both before and during each
upright tilt (21). All variables were aver-
aged for each 1-min data segment during
upright tilting, and each segment of raw
blood pressure, electrocardiogram, and
cerebral Doppler signal was manually ex-
amined for artifacts.
Measures of total peripheral resis-
tance (TPR) for each heart beat were de-
termined from the beat-to-beat blood
pressure signal using commercially avail-
ablesoftware(FinapresMedicalSystems).
This software uses an arctangent model
(22) and has been validated for use in the
older adult population (23). TPR was
measured on a beat-to-beat basis and av-
eraged for each 1-min data segment dur-
ing upright tilting.
Statistical analysis
All data analysis was done in a blinded
fashion.Resultsareexpressedasmeans
SEM.Oursamplesizecalculationsforour
primary outcome measures (systolic
blood pressure, mean blood pressure, di-
astolicbloodpressure,andTPR)assumed
a power of 90% and a 1.25% level of sig-
niﬁcance. After a Bonferroni correction
for multiple comparisons, we found that
we required a sample size of at least 20
subjects to detect a 5% difference in our
primary outcome measures, assuming a
syncope-related incompletion rate of ﬁve
subjects. Mean values for each variable
were determined for each minute of up-
right tilt. A two-way ANOVA with re-
peatedmeasureswasusedtocomparethe
response to 10 min of tilting between ses-
sions (time  session) for all parameters
(24). P  0.0125 was considered signiﬁ-
cant with Bonferroni correction for mul-
tiple comparisons (24).
RESULTS— Characteristics of the
subjects are shown in Table 1. The sub-
jects had an average age of 71.4  0.4
years. They all had reasonable control of
their blood glucose as shown by their
meanSEMfastingbloodglucose(6.5
0.1 mEq), 2-h glucose tolerance test
(11.4  0.2 mEq), and A1C (6.2 
0.05%). Weight (85.9  1.2 kg) and
height (173.9  0.8 cm) indicated a sub-
ject population that was mildly over-
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28.2  0.2 kg/m
2. None of the subjects
had any new health issues or medication
changes between the two sessions.
Effects of euglycemic-
hyperinsulinemic clamps
Mean  SEM insulin levels were signiﬁ-
cantly different (P  0.001) between the
insulin (903  121 pmol/l) and placebo
(161  22 pmol/l) sessions during the
low-doseinfusion(Table1).Similarly,in-
sulin levels were signiﬁcantly different
(P0.001)betweentheinsulin(1,785
239 pmol/l) and placebo (163  23
pmol/l) sessions during the high-dose
infusion.
Neitherthelow-doseorthehigh-dose
euglycemic-hyperinsulinemic clamps
produced any signiﬁcant changes in sys-
tolic (P  0.101), mean (P  0.111), or
diastolic(P0.105)bloodpressurecom-
pared with placebo (by two-way AVOVA
with repeated measures). Similarly, heart
rate (P  0.491), SBFV (P  0.191),
MBFV (P  0.837), and DBFV (P 
0.769) did not demonstrate any signiﬁ-
cant change with the two doses of eugly-
cemic-hyperinsulinemic clamps.
Hemodynamic responses to upright
tilting
Four subjects experienced presyncope
during both the low-dose and high-dose
tilts. The length of time on the tilt table
ranged from 4.3 to 9.75 min for those
who experienced presyncope. Presynco-
pal low-dose tilt subjects had a range of
blood pressures from 91/52 (mean 62) to
98/61 (72) mmHg and a range of heart
rates from 65 to 90 bpm just before dis-
continuing the tilt table test. Presyncopal
high-dose tilt subjects had a range of
blood pressures from 62/42 (48) to 86/51
(62) mmHg and a range of heart rates
from85to89bpmjustbeforediscontinu-
ing the tilt table test.
When these subjects were excluded
fromtheanalysis,therewasnosigniﬁcant
effectofinsulinontheresponseofsystolic
(P  0.992), mean (P  0.962), or dia-
stolic (P  0.959) blood pressure com-
pared with placebo (by two-way AVOVA
with repeated measures) during the low-
dose tilt (Table 1). During the high-dose
tilt, subjects demonstrated a signiﬁcantly
larger drop in mean (P  0.005) and di-
astolic (P  0.008) blood pressure over
time. As shown in Fig. 1, this drop in
blood pressure became signiﬁcant during
the 8th and 9th min (t8 and t9). The dif-
ference between the two sessions with
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proached, but did not reach, statistical sig-
niﬁcance (P0.014) for the high-dose tilt.
Despite the increased orthostatic drop with
insulin during the high-dose tilt, there was
nosigniﬁcantdifferenceintheheartratere-
sponse (P  0.979, low-dose tile; P 
0.273, high-dose tilt) between the insulin
andsalinesessions(Fig.2).AsshowninFig.
3,therewasalsonosigniﬁcantdifferencein
totalperipheralresistanceduringtheeugly-
cemic-hyperinsulinemic clamp compared
with placebo (P  0.047) during the high-
dose tilt or low-dose tilt (P  0.897).
MCA velocity measures during
upright tilt
Excluding subjects who were unable to
complete the tilt test because of presyn-
cope, there was no difference in the re-
sponse of SBFV (P  0.356), MBFV (P 
0.616), or DBFV (P  0.391) to upright
tilting between the insulin and saline ses-
sions during the low-dose tilt (Table 1).
Similarly, there was no difference in the
response of SBFV (P  0.805), MBFV
(P0.125),orDBFV(P0.232)during
the high-dose tilt (Table 1).
CONCLUSIONS — Our study dem-
onstrated signiﬁcant impairment of the
ability to maintain blood pressure under
orthostaticstressduringconditionsofeu-
glycemia hyperinsulinemia. Subjects
demonstrated presyncope during both
doses of hyperinsulinemia that was not
found during the saline sham clamp ses-
sions. This orthostatic intolerance was
alsodosedependent,asshownbythefact
that only the high-dose tilt (80 mU   m
2
  min
1) demonstrated lower blood pres-
sures. Presyncope during euglycemic-
hyperinsulinemic upright tilt was possibly
due to a decrease in total peripheral resis-
tance(althoughthisdidnotreachstatistical
signiﬁcance) or to an impaired tachycardic
response to tilt-induced hypotension.
The opposing effects of insulin on
standing blood pressure are well estab-
lished and are due to the conﬂicting ef-
fects of an adrenergic response (4) in
conjunction with a direct vasodilatory re-
sponse (5). A subcutaneous dose of insu-
lin was shown in a small study of young
subjects with type 1 diabetes (seven sub-
jects with autonomic neuropathy and
seven without autonomic neuropathy) to
produce lower standing blood pressures
only in the setting of baseline autonomic
neuropathy-induced orthostatic hypo-
tension (9). In those young subjects with
autonomic neuropathy, the consequent
sympathetic nervous system dysfunction
allowed the vasodilatory response to in-
sulin to predominate, resulting in lower
standing blood pressures (9). Contrary to
these results, in the present study, from
which subjects with orthostatic hypoten-
Figure 1—Blood pressure response to high-dose tilt. During the high-dose tilt (80 mU   m
2  
min
1 insulin infusion), subjects demonstrated a signiﬁcantly larger drop in mean arterial pres-
sure (MAP) (P  0.005) and diastolic blood pressure (DBP) (P  0.008) over time during the
insulin session. The difference with respect to systolic blood pressure (SBP) did not reach statis-
tical signiﬁcance (P  0.014). This drop in blood pressure became signiﬁcant during the 8th and
9thmin(t8andt9).t0tot9,eachofthe10minofthetilttabletest;r1andr2,theﬁrsttwopost-tilt
recovery minutes; F, SBP-insulin; E, SBP-placebo; Œ, MAP-insulin; ‚, MAP-placebo; f, DBP-
insulin;  , DBP-placebo.
Figure2—Heartrateresponsetolow-andhigh-dosetilts.Despitethedropinbloodpressureseen
during the high-dose tilt, there was no signiﬁcant difference in the heart rate response (low-dose
tilt P  0.979; high-dose tilt P  0.273) between the insulin and saline sessions (Fig. 3). F,
low-dose insulin; E, low-dose placebo; Œ, high-dose insulin; ‚, high-dose-placebo.
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thostatic intolerance in older subjects
with type 2 diabetes. The most likely ex-
planation for this result is that our sub-
jectsweremucholderthanthesubjectsin
previousstudies.Itiswellestablishedthat
the aging process itself results in adrener-
gic insensitivity (10). Insensitivity to an
insulin-mediated increase in adrenergic
activity could allow the vasodilatory re-
sponse to predominate in older subjects,
thereby uncovering orthostatic hypoten-
sion that was not present at baseline. This
hypothesis is supported by prospective
epidemiological data demonstrating an
association between insulin use and syn-
cope in older adults (7). To our knowl-
edge, no previous study has directly
examined the effects of hyperinsulinemia
ontilttableresponsesinolderadultswith
diabetes.
Adrenergic insensitivity as a potential
mechanism underlying hyperinsuline-
mia-associated orthostatic intolerance in
older adults is supported by several ﬁnd-
ings in the present study. First, older sub-
jects with type 2 diabetes demonstrated
no signiﬁcant difference in total periph-
eral resistance during upright tilt in the
high-dose insulin session (there was a
nonsigniﬁcant trend toward lower total
peripheral resistance, as shown in Fig. 3).
In addition, there was no change in the
heart rate response during upright tilt be-
tween the two sessions (Fig. 2) despite
larger decreases in blood pressure with the
high-dose insulin infusion. This result sug-
gests age-associated insensitivity to the in-
sulin-induced adrenergic response, both at
the vascular and chronotropic levels.
Despite the fact that more episodes of
syncope occurred during the upright tilt
with insulin infusion, there was no differ-
ence in the response of Doppler measures
of MCA velocity when the two sessions
were compared. This is probably because
of the fact that for ethical reasons the tilt
table tests were discontinued at the onset
of presyncopal symptoms, as opposed to
allowing the subjects to continue the test
and proceed to an outright syncopal spell.
ThelackofasigniﬁcantdifferenceinDopp-
ler measures of MCA velocity also indicates
thatcerebralautoregulationremainedintact
in the presence of an orthostatic stress dur-
ing euglycemic hyperinsulinemia.
Clinical implications
As shown in Fig. 1, insulin infusion
caused a statistically signiﬁcant worsen-
ing of orthostatic tolerance, resulting in
presyncopal symptomatology in four pa-
tients during insulin. Although the ob-
served exaggeration in the orthostatic
drop with insulin would be unlikely to be
a sole cause for syncopal spells in older
adults with diabetes, it could contribute
to orthostatic hypotension in combina-
tion with other factors such as hyperther-
mia (11), hypovolemia, and adverse
effects from medications (2).
Limitations
Further research is needed to determine
the clinical signiﬁcance of insulin-
mediated orthostatic hypotension in
older adults with diabetes. Although our
results were consistent with age-related
adrenergic insensitivity as an explanatory
mechanism, more research is needed to
determine the underlying cause of this
phenomenon.Someofoursubjectscould
still have had a mild sensory neuropathy,
as we used an insensitive method (physi-
cal examination maneuvers) to screen for
thiscondition.Someofoursubjectscould
also have had a mild autonomic neurop-
athy, as only orthostatic changes in
blood pressure were used to screen for
this condition.
In summary,wedemonstratedthathy-
perinsulinemia results in symptomatic or-
thostatic intolerance in older adults with
type2diabetes.Thisﬁndingwasmostlikely
duetoanage-associatedadrenergicinsensi-
tivityallowingthedirectvasodilatoryaction
of insulin to predominate.
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